



**Commercial/Health Care Exchange Quantity Limit Criteria**  
*Effective: May 8<sup>th</sup>, 2019*

**Quantity Limit Name:** Oxervate

**Products Affected:** Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

8 kits per affected eye per lifetime.

16 kits total per lifetime.

\*Note: Reauthorization will not be approved as there have been no studies to document the efficacy of treatment beyond a single 8-week course.

**References:**

1. Oxervate [prescribing information]. Boston, MA: Dompé U.S. Inc.; April 2019.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	4/12/2019

Last Res. April 12<sup>th</sup>, 2019